Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Quotient Sciences, a drug development and manufacturing accelerator, completed major investments and expansions at its Nottingham, UK and Reading, UK, facilities to support the delivery of fully integrated drug development programs through the ...
read more
Tuesday, October 16, 2018
Quotient Sciences announces an expansion to its operations in the U.S. with the opening of a state-of-the-art, 45,000-square-foot facility located near Philadelphia, in Garnet Valley, Pa.
read more
Wednesday, December 12, 2018
Quotient Sciences announced a collaboration to utilize Quotient’s integrated Translational Pharmaceutics platform to advance the development of DRGT-46.
read more
Thursday, February 17, 2022
Quotient Sciences has integrated drug substance into its flagship Translational Pharmaceutics® platform. The newly integrated service unites drug substance, drug product and clinical testing activities all within a unified organization and under a ...
read more
Quotient Sciences announced the appointment of Thierry Van Nieuwenhove as its new Chief Executive Officer (CEO), effective 16th October 2023.
read more
Quotient Sciences has announced the appointment of Claes Glassell as non-executive chairman of its board of directors.
read more
Quotient Sciences, the drug development and manufacturing accelerator, announced a £6.3 million-pound investment in its recently acquired manufacturing facility in Alnwick, U.K. The investment will significantly expand Quotient’s drug substance ...
read more
Wednesday, September 11, 2024
VS-041, a novel and potentially life-saving treatment for heart failure, developed by Vasa Therapeutics, a San Diego-based biotechnology company, has reached a major clinical milestone with the first human subjects dosed at Quotient Sciences’ ...
read more
Monday, December 08, 2025
Quotient Sciences and Intrepid Labs announced a multi-year strategic partnership to advance the use of artificial intelligence (AI) in early drug development.
read more
Tuesday, September 02, 2025
Quotient Sciences and UK technology innovation center, CPI, have signed a memorandum of understanding (MoU) to form a Joint Venture (JV) aimed at accelerating the development of RNA-based therapies.
read more
Tuesday, October 14, 2025
Quotient Sciences and Biorasi have announced a strategic partnership aimed at streamlining early phase clinical trials from Investigational New Drug (IND) applications to patient proof-of-concept (POC) milestones.
read more
Friday, November 17, 2017
Quotient Sciences has acquired Pharmaterials, a contract development and manufacturing organization.
read more
Thursday, February 11, 2021
Quotient Sciences has acquired Arcinova, a U.K.-based multiservice CDMO.
read more
Quotient Sciences announced the launch of Arcinova - a science-driven service brand for early development that will operate within Quotient Sciences.
read more
Quotient Clinical, the Translational Pharmaceutics Company, has announced the extension of its Translational Pharmaceutics™ platform into patient-focused cancer drug development. Quotient will employ its real-time, flexible manufacturing capabilities...
read more